Tempus AI(TEM)

Material Event filed 2026-07-30

Material Event filed 2026-07-20

Material Event filed 2026-07-20

Material Event filed 2026-05-22

Background The prognostic value of FGFR3 pathway activation in patients with muscle- invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy (NAC) has not been established. Activation of FGFR3 signaling drives a subset of urothelial bladder cancers and classically results from pathogenic gene mutations (mut) or fusions (fus). Additionally, an RNA signature (FGFR-PRS) representing activation of … Continued The post Impact of FGFR3 Pathway Activation in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy appeared first on Tempus .

Background HLA genotyping, specifically HLA-A*02:01 is an actionable marker in uveal melanoma for Tebentafusp, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, with ongoing clinical trials investigating its use in HLA-A*02:01 positive cutaneous and mucosal melanoma. However, prior work has shown a discrepancy in this marker between blood and somatic tumor testing (Seedor R et … Continued The post A New HLA Genotyping Algorithm Shows Extremely High Accuracy and Concordance Between Tumor and Normal Samples appeared first on Tempus .

Background Categorizing gene fusions as drivers or passengers is a data-intensive challenge requiring manual interventions in all but the most well-established biomarkers. The large numbers of structural variants identified from genomic assays require a combination of tools to prioritize clinically relevant mutations in a timely manner. Recent advances in artificial intelligence (AI) and AI-agents have … Continued The post Retrospective Evaluation of an AI-Based Fusion Prioritization Agent for Oncogenicity Assessment in Clinical Sequencing appeared first on Tempus .

Background Patients with breast cancer frequently experience anxiety and depression, yet systemic delays in psychiatric care often leave oncologists to manage these conditions. The recent adoption of DPYD genotyping into NCCN guidelines for fluoropyrimidine safety marks a shift toward routine pharmacogenomic (PGx) integrations in oncology. This creates an opportunity to expand PGx to supportive care, … Continued The post Provider Insights and Utilization of Psychiatric Pharmacogenomics for Patients With Comorbid Breast Cancer and Emotional Distress appeared first on Tempus .

Background Neuroendocrine carcinoma (NEC) of the bladder is a rare and aggressive cancer with limited treatment options. Recent studies reported molecular subtypes resembling small cell lung cancer (SCLC), specifically those associated with transcription factors (TFs) ASCL1, NEUROD1, and POU2F3. A subset of bladder NEC remains unclassified. ATOH1 was recently identified as a TF associated with … Continued The post Molecular Classification of Neuroendocrine Carcinoma of the Bladder appeared first on Tempus .

Background ESR1 mutations (ESR1m) are known drivers of resistance to aromatase inhibitors. While ESR1m has been linked to worse survival outcomes, clonal complexity over time has not been well-evaluated in a real-world context. Here we characterized longitudinal dynamics of ESR1m, including rare point mutation emergence and polyclonality in hormone receptor- positive/HER2-negative metastatic breast cancer (HR+/HER2- … Continued The post ESR1 Mutation Longitudinal Dynamics in RWD Cohort of HR+/HER2- Metastatic Breast Cancer Patients Treated With Standard of Care Hormonal Therapy appeared first on Tempus .

Background Immune checkpoint inhibitors (ICI) have altered the oncology treatment landscape with improved outcomes. Despite approved predictive biomarkers for ICI such as TMB, refining selection can identify more patients (pts) who may benefit, as most TMB-H pts still fail to achieve response, a critical translational gap. Here we introduce IPS, a validated multimodal DNA-/RNA-based molecular … Continued The post Multimodal Immune Profile Score (IPS) Signature as a Predictive Response Biomarker to Immune Checkpoint Inhibitors in Tumor Mutational Burden-High (TMB-H) Advanced Pancancer Cohorts appeared first on Tempus .